Managing ADC Toxicities on Lung Cancer Considered

IASLC shared a post on X:

“Anti Drug Conjugates represent a new way of treating thoracic, breast and gastrointestinal cancers.

Despite recent successes, many ADCs failed during clinical development due to excessive toxicities and unfavorable risk-benefit profiles.

In this episode of Lung Cancer Considered, host Narjust Florez discusses ADCs, and how clinicians can manage some of these toxicities.

With Benjamin Levy and Paolo Tarantino.”